Experience

Erasca, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Principal Scientist

  • Mar 2021 - Present

  San Diego, California, United States



Self-employed

• Real Estate
• 1 - 100 Employee

• In Transit

  • Oct 2020 - Feb 2021

  Great time with family refreshing my mind for drug discovery research



Voronoi

• Netherlands
• Design Services
• 1 - 100 Employee

• CTO

  • Jun 2018 - Sep 2020

  Yeonsu-gu, Incheon, Korea Evaluated cutting-edge researches among leading scientific groups (in industries and academia) and sought licensing-in possibilities. Managed and performed academic and industrial collaborations in Boston to advance hit-to-lead/lead-to-candidate processes for ongoing small molecule inhibitors with cross-functional, multidisciplinary scientists including structural biologists, medicinal chemists, computational scientists, and biologists. Mentored and trained teams and scientists in various… Show more Evaluated cutting-edge researches among leading scientific groups (in industries and academia) and sought licensing-in possibilities. Managed and performed academic and industrial collaborations in Boston to advance hit-to-lead/lead-to-candidate processes for ongoing small molecule inhibitors with cross-functional, multidisciplinary scientists including structural biologists, medicinal chemists, computational scientists, and biologists. Mentored and trained teams and scientists in various stages of projects in cell biology, protein chemistry, molecular biology, biochemistry, & X-ray crystallography. Key Achievements:  Evaluated and proposed novel kinase targets as potential pipelines; two novel targets entered into the early discovery researches  Played an integral role in managing the international collaboration in the development of kinase inhibitors for cancer treatment; one project was advanced to the lead compound stage preparing an international patent filing, and the related small molecule inhibitor is in preparation for IND filing  Pioneered and established new technology (degrader (PROTAC) modality) within the company resulting in the launch of two degrader-based initiatives and file a patent for a set of degraders Show less



Dana-Farber Cancer Institute

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Visiting Scientist

  • Jun 2018 - Sep 2020

  Boston, Massachusetts, United States Managed and oversaw international collaboration focused on kinase drug discovery projects. Led scientists and carried out experiments in various stages of projects in protein chemistry, & X-ray crystallography. Developed technical details of cellular assays for bispecific degraders (PROTACs) and coordinated proteomics experiments to identify potent degraders targeting oncogenic kinases as well as novel degrader targets Key Achievements:  Developed and performed cellular assays and… Show more Managed and oversaw international collaboration focused on kinase drug discovery projects. Led scientists and carried out experiments in various stages of projects in protein chemistry, & X-ray crystallography. Developed technical details of cellular assays for bispecific degraders (PROTACs) and coordinated proteomics experiments to identify potent degraders targeting oncogenic kinases as well as novel degrader targets Key Achievements:  Developed and performed cellular assays and orchestrated proteomics experiments to identify potent bispecific degraders (PROTACs) targeting various kinases; a potent degrader was identified and proceeded to in vivo preclinical studies  Managed and coordinated the international collaboration between the company and the Institute through strong and effective communication skills, and drive to accomplish the project goals; four X-ray crystallographic complex structures were obtained and one small molecule compound was advanced to lead optimization Show less



Daegu Gyeongbuk Medical Innovation Foundation, New Drug Development Center

• Deputy Director

  • Mar 2017 - May 2018

  Daegu, South Korea Led the teams working on employing structure-based and virtual-based drug design processes for drug discovery projects. Managed academic and industrial collaborations with hands-on experience to derive potent small molecule inhibitors by effectively working with a multidisciplinary team of scientists including medicinal chemists, computational scientists, and biologists. Trained, mentored, and coached 12 direct reports (scientists). Key Achievements:  Played an integral role in the… Show more Led the teams working on employing structure-based and virtual-based drug design processes for drug discovery projects. Managed academic and industrial collaborations with hands-on experience to derive potent small molecule inhibitors by effectively working with a multidisciplinary team of scientists including medicinal chemists, computational scientists, and biologists. Trained, mentored, and coached 12 direct reports (scientists). Key Achievements:  Played an integral role in the development of kinase inhibitors for cancer treatment; the team was awarded two patents after successful testing.  Supported a technology transfer for two of the patents and performed experiments to provide biochemical analysis data for the drug candidates.

• Team Leader

  • Jul 2016 - May 2018

  Daegu, South Korea Promoted to Team Lead after demonstrated strong leadership capabilities. Recognized by the team for hands-on experience, management, transparent leadership, and effective communication. Key Achievements:  Performed structure-based drug discovery experiments and worked cohesively with a professional team to solve more than 20 protein structures in three years.

• Principal Scientist

  • Jan 2015 - May 2018

  Daegu, South Korea Performed structure- and fragment-based drug discovery. Delivered data-driven analytical research as a member of a high-functioning multidisciplinary team. Analyzed biophysical properties of 60+ compounds with 30+ target proteins. Key Achievement:  Supported team members in the publication of over five strategic and significant results in leading scientific journals over a three-year period.



Yale University School of Medicine

• United States
• Research Services
• 700 & Above Employee

• Associate Research Scientist

  • Jan 2010 - Dec 2014

  333 Cedar St. New Haven, CT 06520 PI: Dr. Joseph Schlessinger Directed collaborations with multidisciplinary scientists, including medicinal chemists, computational chemists, and biologists, to derive potent small molecule inhibitors for Fibroblast Growth Factor receptors (FGFRs). Trained and supported graduate students and postdoctoral fellows in protein chemistry, molecular biology, and X-ray crystallography. Leveraged educational background with a strong ability to communicate complex information to novice students… Show more PI: Dr. Joseph Schlessinger Directed collaborations with multidisciplinary scientists, including medicinal chemists, computational chemists, and biologists, to derive potent small molecule inhibitors for Fibroblast Growth Factor receptors (FGFRs). Trained and supported graduate students and postdoctoral fellows in protein chemistry, molecular biology, and X-ray crystallography. Leveraged educational background with a strong ability to communicate complex information to novice students. Recognized for leading engaging projects using cutting-edge technology and software. Key Achievements:  Published cutting-edge receptor tyrosine kinases studies in scientific journals including PNAS.  Awarded a world patent for work concerning Inhibitors of ligand-induced trans autophosphorylation of receptor tyrosine kinases (RTK) and use in treating RTK-associated diseases.  Trained, mentored, and coached five graduate students and one postdoctoral fellow.

• Postdoctoral Fellow

  • Jan 2004 - Dec 2009

  PI: Dr. Joseph Schlessinger Conducted cellular assays and X-ray crystallographic studies on signaling pathways of FGFRs. Supported ongoing structural researches on FGFR signal transduction. Trained undergraduate and graduate students in X-ray crystallography. Key Achievements:  Published a first structural study on novel interface formation between FGFR1 and its downstream substrate in Cell (2009).  Supported and became co-authored for ongoing projects on signal transduction of… Show more PI: Dr. Joseph Schlessinger Conducted cellular assays and X-ray crystallographic studies on signaling pathways of FGFRs. Supported ongoing structural researches on FGFR signal transduction. Trained undergraduate and graduate students in X-ray crystallography. Key Achievements:  Published a first structural study on novel interface formation between FGFR1 and its downstream substrate in Cell (2009).  Supported and became co-authored for ongoing projects on signal transduction of FGFRs published in PNAS.  Trained, mentored, and coached undergraduate and graduate students.



Max-Planck Institute for Biochemistry

• Postdoctoral Fellow

  • Jan 2003 - Dec 2003

  Martinsried, Germany PI: Dr. Robert Huber Incorporated non-canonical amino acids into proteins to obtain novel properties that cannot be achieved with canonical amino acids and solved atomic structures to evaluate the effects of non-canonical amino acid incorporation and to validate their structural integrity. Conducted organic chemistry to synthesize non-canonical amino acids like seleno-tryptophan. Key Achievements:  Published non-canonical amino acid incorporation and their applications in four… Show more PI: Dr. Robert Huber Incorporated non-canonical amino acids into proteins to obtain novel properties that cannot be achieved with canonical amino acids and solved atomic structures to evaluate the effects of non-canonical amino acid incorporation and to validate their structural integrity. Conducted organic chemistry to synthesize non-canonical amino acids like seleno-tryptophan. Key Achievements:  Published non-canonical amino acid incorporation and their applications in four scientific journals as the first- and co-authors.  Co-invented a patent on the crystallographic application of non-canonical amino acids.

• Ph.D Candidate

  • Sep 1999 - Dec 2002

  Advisor: Dr. Robert Huber Protein engineering, chemical synthesis of non-canonical amino acids and their incorporation into proteins, X-ray crystallography